Skip to main content
Novartis AG logo

Novartis AG — Investor Relations & Filings

Ticker · NOVN ISIN · CH0038459415 LEI · 5493007HIVTX6SY6XD66 SW Manufacturing
Open in API
Filings indexed 1,070 across all filing types
Latest filing 2018-04-17 M&A Activity
Country CH Switzerland
Listing SW NOVN

About Novartis AG

https://www.novartis.com/

Novartis AG is a global medicines company focused on the research, development, manufacturing, and marketing of innovative healthcare products. The company's mission is to reimagine medicine to improve and extend people's lives. By leveraging advanced science and technology, Novartis develops a portfolio of treatments across various therapeutic areas to address the evolving needs of patients and societies. The firm is committed to delivering high-value medicines that tackle some of the most challenging healthcare issues worldwide.

Recent filings

Filing Released Lang Actions
FORM 6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K filed by Novartis AG, which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces the commencement of a tender offer by Novartis for AveXis, including details about the offer, related filings (Schedule TO and Schedule 14D-9), and contact information. It is a regulatory announcement about a merger and acquisition activity rather than the merger filing itself or a detailed merger proxy statement. The document is not a full annual or quarterly report, audit report, or earnings release. It is a formal regulatory filing providing information about the tender offer initiation, which fits best under the category of M&A Activity announcements. Therefore, the appropriate classification is TAR (M&A Activity). The document length (9974 characters) and detailed content support this classification with high confidence.
2018-04-17 English
Novartis tender offer for AveXis commences
M&A Activity Classification · 98% confidence The document text explicitly announces the commencement of a cash tender offer by Novartis Finance S.A. (through its subsidiary) to purchase all outstanding shares of AveXis, Inc. It details the offer price, expiration date, and mentions the filing of a Tender Offer Statement on Schedule TO and a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC. These documents (Tender Offer Statement/Schedule TO and Schedule 14D-9) are core components of a tender offer process, which falls under the category of Mergers & Acquisitions (M&A) activity. The closest matching category is 'M&A Activity' (Code: TAR).
2018-04-17 English
SC TO-T Filing
Regulatory Filings
2018-04-17 English
SC TO-C Filing
Regulatory Filings
2018-04-10 English
FORM 6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K filing by Novartis AG, which is a report of a foreign private issuer submitted to the SEC. The content primarily consists of a media release announcing Novartis's agreement to acquire AveXis Inc. for $8.7 billion. It details the transaction terms, strategic rationale, regulatory designations, and expected financial impact. There is no detailed financial data, comprehensive financial statements, or management discussion typical of an Annual Report (10-K) or Interim Report (IR). It is not a transcript of a call, nor a voting result, nor a remuneration report. The document is a regulatory announcement about a significant corporate transaction (M&A activity). Given the detailed description of the acquisition agreement and related information, this fits best under the category of M&A Activity (TAR). The document length (15,000 characters) and content indicate it is the announcement itself, not just a brief notice or a report publication announcement. Therefore, the classification is M&A Activity (TAR) with high confidence.
2018-04-09 English
Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader
M&A Activity Classification · 99% confidence The document is a press release dated April 9, 2018, announcing that Novartis has entered into an agreement to acquire AveXis Inc. for USD 8.7 billion. This announcement details a significant corporate transaction involving the purchase of another company's shares via a tender offer, which falls under the category of Mergers & Acquisitions (M&A) activity. The definition for M&A Activity (Code: TAR) covers 'Announcements and documents related to merger proposals or takeover bids.' The text explicitly discusses the merger agreement, tender offer details, and regulatory filings related to the transaction (Schedule TO, Schedule 14D-9), confirming it is an M&A announcement, not a routine periodic report or a general regulatory filing.
2018-04-09 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.